Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CSTI-500 in Prader-Willi Syndrome
NCT05504395Phase 1Completed
- Sponsor
- ConSynance Therapeutics
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSTI-500 in Prader-Willi syndrome (PWS), sponsored by ConSynance Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at 144 hours, Area Under the Curve 0-72h and 2 more. Started Nov 2022; status: completed.
02
Drugs
CSTI-500
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05504395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504395.